Interestingly, USP18 inhibition promotes the antibacterial effect of TNFα and subsequently induces reactive oxygen species (ROS), thereby controlling primary and secondary bacterial infection, which suggests the therapeutic potential of targeting USP18 in patients to ameliorate disease caused by serious bacterial infections. Here, TNF is linked to bacterial infectious disease.